Please login to the form below
Ranbaxy wins FDA approval for Metformin in US
India-based Ranbaxy Laboratories' 100 per cent-owned Ohm Laboratories has won FDA approval to manufacture and market Metformin tablets in the US.
India-based Ranbaxy Laboratories' 100 per cent-owned Ohm Laboratories has won FDA approval to manufacture and market Metformin tablets in the US.
Ipca Laboratories, which has a strategic alliance with Ranbaxy, will manufacture the formulation at its facilities in India. Ranbaxy will commercialise the product in the US market, Ipca revealed in a press statement to the Bombay Stock Exchange.
Total annual US sales for Metformin, an insulin sensitising agent, was USD 379m, according to Ranbaxy.
Share
Related Hub content
Featured jobs
-
Associate Director, Healthcare PR
-
£60, 000 – £67, 000+ benefits
- CALLING ALL SENIOR HEALTHCARE PR FREELANCERS!!!!! ACCOUNT DIRECT...
-
EXCELLENT DAY RATES AVAILABLE
- Medical Writer - Medical Communications
-
£30, 000 - £40, 000 according to skills and experience plus benefits
-
Senior Medical Writer
-
Great salary and bebefits
- Editorial Team Leader or Scientific Director
-
£50, 000 - £55, 000 benefits
-
Scientific Director
-
Great salary and bebefits
- Senior Account Director or Business Unit Director, Healthcare Ad...
-
C£60, 000 – £70, 000 benefits
-
Scientific Engagement Director
-
Salary will be dependant on experience
- Assistant Product Manager - Hertfordshire
-
Competitive salary depending on experience benefits
-
Account Manager, Healthcare PR
-
£40, 000 – £42, 000 great benefits and bonuses
- Senior Account Manager / Account Director
-
Great salary and bebefits
- Sales & Marketing Manager - New Launch - Mental Health - S E...
-
Highly Competitive Basic, Bonus &Benefits
-
Product Manager - Hertfordshire
-
Competitive salary depending on experience benefits
-
Account Manager
-
£40, 000 - £45, 000 benefits
Subscribe to our email news alerts
- Novo Nordisk expands cell therapy R&D, says type 1 diabetes cure a step closer
- FDA starts review of Sanofi’s oral type 1 diabetes drug
- Moving annual total (MAT)
- Key success factor (KSF)
- Foundry3 set sights on tailored patient support programmes
- Roche’s Hemlibra first drug to top standard therapy in haemophilia A
- Daily Brief: GDPR and NHS Opt Out Day, BioMarin's new rare disease approval and more
- Synergy Vision shortlisted as finalists for two awards at the 2018 Communiqué Awards
- AstraZeneca expands alliance with Bicycle Therapeutics
- AbbVie trial backs chemo-free Imbruvica combo regimen
- The call for a more strategic medical affairs community
- Transparency and accountability: tackling opacity and blame head-on
PMHub
Adelphi Research UK
Adelphi Research UK is a healthcare insight partner. We uniquely blend robust market research with a consultancy approach, to guide...
Latest intelligence
- Beyond the event
- ...
- Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
- Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
- Is the pharma business model ready for precision medicine?
- Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
Quick links
Infographics
